Workenhe ST - Search Results

1

Determinants for Antitumor and Protumor Effects of Programmed Cell Death.

Workenhe ST, Inkol JM, Westerveld MJ, Verburg SG, Worfolk SM, Walsh SR, Kallio KLF. Workenhe ST, et al. Cancer Immunol Res. 2024 Jan 3;12(1):7-16. doi: 10.1158/2326-6066.CIR-23-0321. Cancer Immunol Res. 2024. PMID: 37902605 Free PMC article.

2

Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Workenhe ST, Ketela T, Moffat J, Cuddington BP, Mossman KL. Workenhe ST, et al. Oncogene. 2016 May 12;35(19):2465-74. doi: 10.1038/onc.2015.303. Epub 2015 Aug 10. Oncogene. 2016. PMID: 26257065

3

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, Pol J, Bramson JL, Wan Y. Nguyen A, et al. Among authors: workenhe st. Cell Rep. 2018 Jul 17;24(3):642-654. doi: 10.1016/j.celrep.2018.06.040. Cell Rep. 2018. PMID: 30021162 Free article.

4

Tumor-intrinsic determinants of immunogenic cell death modalities.

Workenhe ST, Pol J, Kroemer G. Workenhe ST, et al. Oncoimmunology. 2021 Mar 2;10(1):1893466. doi: 10.1080/2162402X.2021.1893466. Oncoimmunology. 2021. PMID: 33717656 Free PMC article. Review.

5

Viral-mediated activation and inhibition of programmed cell death.

Verburg SG, Lelievre RM, Westerveld MJ, Inkol JM, Sun YL, Workenhe ST. Verburg SG, et al. Among authors: workenhe st. PLoS Pathog. 2022 Aug 11;18(8):e1010718. doi: 10.1371/journal.ppat.1010718. eCollection 2022 Aug. PLoS Pathog. 2022. PMID: 35951530 Free PMC article. Review.

6

Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells.

Inkol JM, Westerveld MJ, Verburg SG, Walsh SR, Morrison J, Mossman KL, Worfolk SM, Kallio KL, Phippen NJ, Burchett R, Wan Y, Bramson J, Workenhe ST. Inkol JM, et al. Among authors: workenhe st. J Immunother Cancer. 2024 Apr 4;12(4):e006781. doi: 10.1136/jitc-2023-006781. J Immunother Cancer. 2024. PMID: 38580330 Free PMC article.

7

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Workenhe ST, et al. Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19. Cancer Immunol Res. 2013. PMID: 24777969

8

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.

van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW. van Vloten JP, et al. Among authors: workenhe st. J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021. J Immunol. 2018. PMID: 29311387 Review.

9

Cytokines in oncolytic virotherapy.

Pol JG, Workenhe ST, Konda P, Gujar S, Kroemer G. Pol JG, et al. Among authors: workenhe st. Cytokine Growth Factor Rev. 2020 Dec;56:4-27. doi: 10.1016/j.cytogfr.2020.10.007. Epub 2020 Nov 2. Cytokine Growth Factor Rev. 2020. PMID: 33183957 Free article. Review.

10

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors.

Workenhe ST, Nguyen A, Bakhshinyan D, Wei J, Hare DN, MacNeill KL, Wan Y, Oberst A, Bramson JL, Nasir JA, Vito A, El-Sayes N, Singh SK, McArthur AG, Mossman KL. Workenhe ST, et al. Commun Biol. 2020 Nov 4;3(1):645. doi: 10.1038/s42003-020-01362-w. Commun Biol. 2020. PMID: 33149194 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page